BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Dako A/S and Epitomics, Inc. Enter into Strategic Alliance on Developing and Launching State-Of-The-Art IHC Diagnostic Monoclonal Antibodies


3/21/2011 8:26:57 AM

GLOSTRUP, DENMARK--(Marketwire - March 21, 2011) - Dako Denmark A/S and the Rabbit Monoclonal Antibody Company, Epitomics, Inc., announced today that they have entered into a collaboration which will allow the companies to unite competencies to provide the Anatomic Pathology market with state-of-the-art antibodies.

"Dako is on a mission to fight cancer. We are therefore very pleased to announce this strategic alliance that will combine the competencies of Dako and Epitomics to establish the optimal portfolio of very high quality rabbit monoclonal antibodies to be used in diagnosing cancer and in developing predictive assays to the benefit of cancer patients all over the world," says Lars Holmkvist, CEO of Dako Denmark A/S.

"The strategic alliance with Dako is an important endorsement of RabMAbs in the field of immunohistochemistry (IHC) for anatomic pathology - a rapidly growing market. In recent years Epitomics has accumulated a collection of companion diagnostics antibodies in the field of pathology. This alliance will take us to the next level," says Dr. Guo-Liang Yu, President and CEO of Epitomics, Inc.

Dako's expertise within the field of human cancer diagnostics, including development of new diagnostic antibodies relevant in identifying, differentiating and characterizing tumors, and Epitomics' exclusive intellectual property rights and expertise within development and production of rabbit monoclonal antibodies are the key ingredients to future development of routine diagnostics, prognostics and predictive immunohistochemical assays, also known as companion diagnostics or PharmacoDiagnostics (PharmDxTM).

"The exploitation of Dako's market-leading approach in supplying automated system solutions within diagnostic immunohistochemistry, and Epitomics' technical superiority within generation of rabbit monoclonal antibodies will bring new and previously unseen high-quality diagnostic tools to the routine pathology community," says Lars Holmkvist.

Besides the development and launch of new state-of-the-art monoclonal antibodies the strategic alliance between Dako and Epitomics also includes a technology transfer from Epitomic's to Dako's facilities.

The financial terms of the agreement were not disclosed.

About Dako

Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics. Hospital and research laboratories worldwide use Dako's know-how, reagents, instruments and software to make precise diagnoses and determine the most effective treatment for patients suffering from cancer. Employing more than 1,000 people and being present in more than 80 countries, Dako covers essentially all of the anatomic pathology markets globally. Dako is owned by a private equity fund, EQT. www.dako.com

About Epitomics

Epitomics, Inc., an emerging biotechnology company, is dedicated to developing breakthrough monoclonal antibody technology for research, diagnostic and therapeutic applications. The company utilizes a unique and proprietary RabMAb® (Rabbit Monoclonal Antibody) technology which produces antibodies with superior binding affinity and bioactivity in a wide variety of biological assays. Epitomics, Inc. is headquartered in Burlingame, California, and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China. www.epitomics.com

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Dako Denmark A/S via Thomson Reuters ONE

[HUG#1498495]


Media contacts

Maia Fredtoft Sochting
Dako Denmark A/S
25 46 10 83
Email Contact

Abe Couse
Epitomics, Inc.
650-583-6688
Email Contact


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->